Stimuli-Responsive Insulin Delivery Devices.
Stephanie FuchsKaavian ShariatiMinglin MaPublished in: Pharmaceutical research (2020)
The development of new diabetes treatment strategies has garnered much interest given that conventional management therapies for type 1 diabetes fail to provide optimal glycemic control while creating a high burden of self-care to patients. Stimuli-responsive, "closed-loop" systems are particularly attractive due to their ability to mimic dynamic ß cell function by releasing insulin in response to fluctuating glucose levels in real-time and with minimal patient discomfort. In this short review, we focus on stimuli-responsive, reservoir-based insulin delivery devices. We explore and evaluate systems that are either physiologically or externally triggered. While obstacles remain before such technologies can be translated to clinical settings, further optimization of delivery systems forebodes that these technologies will have a tremendous impact on type 1 diabetes treatment.
Keyphrases
- glycemic control
- type diabetes
- blood glucose
- end stage renal disease
- cancer therapy
- weight loss
- insulin resistance
- newly diagnosed
- chronic kidney disease
- ejection fraction
- cardiovascular disease
- prognostic factors
- peritoneal dialysis
- case report
- metabolic syndrome
- adipose tissue
- drug delivery
- blood pressure
- combination therapy